
Imlifidase Enables Gene Therapy in AAV-Immune Crigler–Najjar Patients
Genethon, a global leader in gene therapy research for rare genetic diseases, and Hansa Biopharma, a Sweden-based biotechnology company pioneering IgG-cleaving enzyme technology, have announced a major milestone in the field of gene therapy. A patient suffering from Crigler–Najjar syndrome,…








